Table 1 Demographic of patient who underwent virtual challenge
From: Virtually supported penicillin allergy de-labelling during COVID-19
Age | Sex | Comorbidities | Inciting medication | Index reaction | Risk of reactiona | Rationale for virtually supervised challenge based on patient–physician shared decision making | Reactions—immediate or delayedb |
|---|---|---|---|---|---|---|---|
3 | M | Multiple food allergies | Amoxicillin | Generalized urticaria | Intermediate | Convenience–distance | None |
3 | F |  | Amoxicillin | Maculopapular rash | Intermediate | Convenience–distance | None |
4 | M | Cystic fibrosis | Amoxicillin clavulanic acid | Maculopapular rash | Intermediate | Convenience–distance | None |
4 | M | Asthma, atopic dermatitis | Amoxicillin | Maculopapular rash | Intermediate | Convenience–distance | None |
6 | F | Recurrent urinary tract infections, allergic rhinoconjuctivitis | Amoxicillin | Generalized urticaria | Intermediate | Convenience–distance | None |
6 | F | Atopic dermatitis | Amoxicillin | Maculopapular rash | Intermediate | Convenience–distance | None |
6 | F |  | Amoxicillin clavulanic acid | Urticaria | Intermediate | Convenience–distance | None |
8 | F |  | Amoxicillin | Generalized urticaria and facial angioedema | Intermediate | Convenience–distance | None |
8 | M | NSAID allergy | Amoxicillin | Urticaria and angioedema | Intermediate | Convenience–distance | None |
8 | M | Cystic fibrosis | Amoxicillin | Urticaria | Intermediate | Convenience | None |
11 | F | Â | Amoxicillin | Generalized urticaria | Intermediate | Convenience | None |
12 | M | Food allergy (peanut), asthma, allergic rhinoconjunctivitis | Penicillin | Maculopapular rash | Intermediate | Convenience, less missed school days | None |
12 | F | Â | Amoxicillin | Generalized urticaria | Intermediate | Convenience | None |
12 | M | Â | Amoxicillin | Maculopapular rash | Intermediate | Convenience | None |
14 | M | Allergic rhinitis, food allergy, asthma | Amoxicillin | Urticaria | Intermediate | Convenience | None |
19 | F | Asthma | Amoxicillin | Generalized urticaria | Intermediate | Convenience, less missed school days | None |
37 | M | Relapsing Hodgkin lymphoma, thyroiditis, previous stem cell transplant | Amoxicillin | Rash | Intermediate | Reduce hospital/infectious risk exposure | None |
54 | F | Interstitial lung disease on oxygen (end stage) | Amoxicillin | Localized rash on arm | Intermediate | Reduce hospital/infectious risk exposure in patient-high risk for severe COVID19 outcomes | None |
65 | F | Myelodysplastic syndrome, dyslipidemia, hypertension, diabetes | Piperacillin tazobactam | Petechial macules/thin papules coalescing into larger purpuric patches on her upper and lower extremities and including trunk, patient also thrombocytopenic | Intermediate | Reduce hospital/infectious risk exposure in immunosuppressed patient | None |
66 | F | Multiple myeloma awaiting stem cell transplant, hypertension, diabetes | Amoxicillin | Local rash to chest | Intermediate | Â | None |
70 | F | Locally advanced thymic tumour, hypertension, diabetes | Penicillin | Urticaria | Intermediate | Reduce hospital/infectious risk exposure in patient-high risk for severe COVID19 outcomes | None |
70 | F | Diffuse large B-cell lymphoma awaiting bone marrow transplant | Penicillin | Unknown | Intermediate | Convenience | None |
71 | M | Interstitial lung disease (end stage) awaiting transplant, emphysema, hypothyroidism, hypertension, dyslipidemia | Penicillin | Local rash | Intermediate | Reduce hospital/infectious risk exposure in patient-high risk for severe COVID19 outcomes | None |